MAIA Biotechnology enrolls first patient in expansion of phase 2 clinical trial for ateganosine in advanced non─small ...
MAIA Biotechnology, Inc, a targeted therapy and immuno-oncology company focused on the development and commercialization of potential first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of …